Viking Therapeutics' obesity drug shows durable weight-loss benefit, shares jump

By Reuters News

Sept 22 (Reuters) - Viking Therapeutics VKTX.O said patients shifted to a less frequent dosing regimen of its experimental obesity treatment showed superior weight loss maintenance in a study than those on placebo, sending its shares up 40% before the bell.

The company said on Tuesday that patients who switched to an every-other-week dosing of VK2735 maintained up to 97% of the weight they had lost during an initial 21-week treatment period, while those who moved to a monthly dosing retained up to 90% of their prior weight loss over the following 12 weeks.

Viking said it plans to study oral maintenance dosing in a future part of the trial.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.